Clinical Data Manager

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) given average rating of "Moderate Buy" by analysts. September 18, 2026 Key points. * Analysts give Monte Rosa Therapeutics a "Moderate Buy" consensus: Six analysts recommend buying the stock, one rates it a strong buy, while two recommend holding or selling. The average 12-month price target is $28.50. * Recent financial results fell short of expectations: Monte Rosa reported a quarterly loss of $0.43 per share versus the expected $0.38 loss, while revenue of $8.97 million missed estimates of $12.91 million. * The stock opened at $12.60, well below analyst targets and recent averages: GLUE has traded between $6.23 and $25.77 over the past year, while institutional investors own nearly 80% of the company and insiders sold 74,427 shares during the latest quarter. * Five stocks we like better than Monte Rosa Therapeutics. Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $28.50. Several brokerages have commented on GLUE. Zacks Research upgraded Monte Rosa Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Weiss Ratings downgraded shares of Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. decreased their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Finally, Wedbush reiterated an "outperform" rating and issued a $27.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, September 9th. Monte Rosa Therapeutics stock down 0.4%. Shares of GLUE opened at $12.60 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -7.16 and a beta of 1.50. The company's fifty day moving average is $17.17 and its two-hundred day moving average is $18.15. Monte Rosa Therapeutics has a fifty-two week low of $6.23 and a fifty-two week high of $25.77. Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.The firm had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million. As a group, equities research analysts anticipate that Monte Rosa Therapeutics will post -1.04 earnings per share for the current year. Insider activity. In other news, insider Sharon Townson sold 6,000 shares of the firm's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the sale, the insider owned 67,845 shares of the company's stock, valued at approximately $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director owned 10,000 shares of the company's stock, valued at $231,100. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 74,427 shares of company stock valued at $1,626,737. Corporate insiders own 6.40% of the company's stock. Hedge funds weigh in on Monte Rosa Therapeutics. A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. bought a new position in shares of Monte Rosa Therapeutics during the second quarter worth about $18,029,000. Squarepoint Ops LLC grew its position in Monte Rosa Therapeutics by 123.6% in the 2nd quarter. Squarepoint Ops LLC now owns 82,953 shares of the company's stock worth $2,007,000 after purchasing an additional 45,846 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Monte Rosa Therapeutics in the second quarter valued at approximately $321,000. HighTower Advisors LLC acquired a new position in shares of Monte Rosa Therapeutics during the second quarter worth approximately $371,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter worth about $273,000. 79.96% of the stock is currently owned by institutional investors and hedge funds. About Monte Rosa Therapeutics. Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule medicines designed to selectively eliminate disease-causing proteins. The company uses its proprietary Tunable Molecular Glue (TME) platform to identify molecular glue degraders that redirect the cell's natural protein-degradation machinery toward specific therapeutic targets. Monte Rosa's research and development programs address areas including autoimmune and inflammatory diseases, as well as cancer. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Monte Rosa Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list. While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates. Continue following MarketBeat

Monte Rosa starts MRT-2359 prostate trial. * Monte Rosa Therapeutics dosed the first patient in a Phase 2 trial of MRT-2359 plus apalutamide for metastatic castration-resistant prostate cancer. * The MODeFIRe-1 study will enroll up to 25 patients with AR mutation-positive mCRPC. * Monte Rosa stated that prior combination data showed PSA responses in 5 of 5 AR-mutant patients in an earlier study. Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer. The trial will enroll up to 25 patients with mCRPC who previously received a second-generation androgen receptor inhibitor and will evaluate treatment responses and safety outcomes. The study will assess PSA responses, RECIST responses, duration of response, radiographic progression-free survival, PSA progression-free survival, and safety, while enrollment in the prior expansion arm with enzalutamide has been completed. Monte Rosa stated that updated data from six AR-mutant patients in the previous expansion arm is expected by year-end. The company previously reported that the enzalutamide combination study showed PSA responses in 5 of 5 AR-mutant patients, a 100% disease control rate, and two RECIST responses among heavily pretreated patients. Monte Rosa Therapeutics develops molecular glue degraders designed to target disease-related proteins, with MRT-2359 being evaluated in cancer indications including AR mutation-positive prostate cancer. Frequently asked questions. GLUE signals